Marketing-authorisation holder · Belgium
Pfizer Europe Ma Eeig
601 medicines in 5 countries, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · Belgium
601 medicines in 5 countries, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 601
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| Abrysvo | Respiratory syncytial virus vaccines | EU (EMA) | Authorised | 2023 |
| ABRYSVOPolvere e solvente per soluzione iniettabile | Respiratory syncytial virus vaccines | Italy | Authorised | |
| Abrysvo poeder en oplosmiddel voor oplossing voor injectiePoeder en oplosmiddel voor oplossing voor injectie | Recombinant respiratoir syncytieel virus subgroep a prefusie f antigeen, Recombinant respiratoir syncytieel virus subgroep b prefusie f antigeen | Netherlands | Authorised | 2023 |
| Abrysvo poeder en oplosmiddel voor oplossing voor injectiePoeder en oplosmiddel voor oplossing voor injectie | Recombinant respiratoir syncytieel virus subgroep a prefusie f antigeen, Recombinant respiratoir syncytieel virus subgroep b prefusie f antigeen | Netherlands | Authorised | 2023 |
| ABRYSVO POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE0,06 mg + 0,06 mg · Polvo y disolvente para solución inyectable | Virus sincitial respiratorio, subgroupo a, subunidad f proteina estabilizada en prefusion, Virus sincitial respiratorio, subgroupo b, subunidad f proteina estabilizada en prefusion | Spain | Marketed | 2023 |
| ACIDO ZOLEDRONICO HOSPIRAConcentrato per soluzione per infusione | Zoledronic acid | Italy | Authorised | |
| Amsparity | Adalimumab | EU (EMA) | Authorised | 2020 |
| Amsparity 20 mg, oplossing voor injectie in voorgevulde spuitOplossing voor injectie | Adalimumab | Netherlands | Authorised | 2020 |
| Amsparity 40 mg, oplossing voor injectieOplossing voor injectie | Adalimumab | Netherlands | Authorised | 2020 |
| Amsparity 40 mg, oplossing voor injectie in voorgevulde penOplossing voor injectie | Adalimumab | Netherlands | Authorised | 2020 |
| Amsparity 40 mg, oplossing voor injectie in voorgevulde spuitOplossing voor injectie | Adalimumab | Netherlands | Authorised | 2020 |
| AROMASIL 25 mg COMPRIMIDOS RECUBIERTOS25 mg · Comprimido recubierto | Exemestane | Spain | Marketed | 2024 |
| AROMASIL 25 MG COMPRIMIDOS RECUBIERTOS25 mg · Comprimido recubierto | Exemestane | Spain | Marketed | 2024 |
| AROMASIL 25 MG COMPRIMIDOS RECUBIERTOS25 mg · Comprimido recubierto | Exemestane | Spain | Marketed | 2018 |
| AROMASIL 25 mg COMPRIMIDOS RECUBIERTOS25 mg · Comprimido recubierto | Exemestane | Spain | Marketed | 2021 |
| BeneFIX | Coagulation factor ix | EU (EMA) | Authorised | 1997 |
| BENEFIXPolvere e solvente per soluzione per infusione endovenosa | Coagulation factor ix | Italy | Authorised | |
| BeneFIX 1000 IE, poeder voor injectievloeistofPoeder en oplosmiddel voor oplossing voor injectie | Coagulation factor ix | Netherlands | Authorised | 1997 |
| BENEFIX 1000 UI, POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE1000 ui · Polvo y disolvente para solución inyectable | Coagulation factor ix | Spain | Marketed | 2007 |
| BeneFIX 1500 IE, poeder voor injectievloeistofPoeder en oplosmiddel voor oplossing voor injectie | Coagulation factor ix | Netherlands | Authorised | 2017 |
| BENEFIX 2000 UI, POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE2000 ui · Polvo y disolvente para solución inyectable | Coagulation factor ix | Spain | Marketed | 2007 |
| BeneFIX 250 IE, poeder voor injectievloeistofPoeder en oplosmiddel voor oplossing voor injectie | Coagulation factor ix | Netherlands | Authorised | 1997 |
| BENEFIX 250 UI, POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE250 ui · Polvo y disolvente para solución inyectable | Coagulation factor ix | Spain | Marketed | 2007 |
| Benefix 3000 IE, poeder en oplosmiddel voor oplossing voor injectiePoeder en oplosmiddel voor oplossing voor injectie | Coagulation factor ix | Netherlands | Authorised | 2012 |
| BENEFIX 3000 UI, POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE3000 ui · Polvo y disolvente para solución inyectable | Coagulation factor ix | Spain | Marketed | 2012 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Romania | 177 | 0 | 177 | CompaniesAll medicines |
| Spain | 175 | 156 | 19 | CompaniesAll medicines |
| Netherlands | 130 | 130 | 0 | CompaniesAll medicines |
| European Union (EMA) | 65 | 53 | 12 | CompaniesAll medicines |
| Italy | 54 | 53 | 1 | CompaniesAll medicines |
Also in the registers of France
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Ministerul Sănătății, Catalogul public naţional al preţurilor, 18 iunie 2021, downloaded 2026-10-08 from data.gov.ro; CC BY 4.0; structured factual adaptation, code whitespace trimmed only where explicitly recorded.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.